Equities researchers at Zacks Research lifted their Q4 2024 earnings estimates for Sarepta Therapeutics in a research note issued to investors on Monday, February 3rd. Zacks Research analyst S.

Management projected strong growth for 2025, driven by expanded reimbursement in key European markets such as Spain and Italy and the expected completion of the post-approval efficacy study (PAES).

Over the last 7 days, the United States market has remained flat, yet it is up 22% over the past year with earnings expected to grow by 15% per annum in the coming years. In this context of steady ...

In a report released today, Anupam Rama from J.P. Morgan maintained a Buy rating on Oric Pharmaceuticals (ORIC – Research Report), with a price ...

Patient advocate Austin Leclaire, who died Feb. 1, played a pivotal role in spurring the development of the first medicines ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in licensing deals, on average, than in 2023 with an eye toward enriching their ...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...